By contrast, in 90 patients with ALK-rearranged adenocarcinoma who received crizotinib, strong PD-L1 expression was significantly associated with an unfavorable clinical outcome with shorter progression-free survival and overall survival. The gene discussed is CD274; the disease is adenocarcinoma.